Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor
Purpose This study aimed to determine the organ-specific accuracy of [ 18 F]FDG-PET/CT in identifying immune-related adverse events (irAEs) in patients with high-risk (stage III/IV) surgically resected melanoma treated with an adjuvant immune checkpoint inhibitor (ICI) and determine the incidence of...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of radiology 2024-07, Vol.42 (7), p.753-764 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 764 |
|---|---|
| container_issue | 7 |
| container_start_page | 753 |
| container_title | Japanese journal of radiology |
| container_volume | 42 |
| creator | Gideonse, Birte Molvik Birkeland, Magnus Vilstrup, Mie Holm Grupe, Peter Naghavi-Behzad, Mohammad Ruhlmann, Christina H. Gerke, Oke Hildebrandt, Malene Grubbe |
| description | Purpose
This study aimed to determine the organ-specific accuracy of [
18
F]FDG-PET/CT in identifying immune-related adverse events (irAEs) in patients with high-risk (stage III/IV) surgically resected melanoma treated with an adjuvant immune checkpoint inhibitor (ICI) and determine the incidence of irAEs within the first year after starting treatment.
Materials and methods
This registry-based study included individuals who had undergone surgical removal of melanoma and were undergoing adjuvant ICI treatment (either nivolumab or pembrolizumab). The study specifically enrolled patients who had undergone both a baseline and at least one subsequent follow-up [
18
F]FDG-PET/CT scan. Follow-up scans were performed every third month in the first year after surgery to screen for disease recurrence. We retrospectively compared the follow-up scans with baseline scans to identify irAEs. Clinical information on irAEs was obtained from medical records and served as a reference standard for determining the accuracy of [
18
F]FDG-PET/CT.
Results
A total of 123 patients with 363 [
18
F]FDG-PET/CT scans were included, and 65 patients (52.8%) developed irAEs. In decreasing order, the organ-specific incidences of irAEs were: skin 26/65 (40%), muscle and joints 21/65 (32.3%), intestines 13/65 (20%), thyroid gland 12/65 (18.5%), lungs 4/65 (6.2%), and heart 2/65 (3.1%). The sensitivities and specificities of [
18
F]FDG-PET/CT for diagnosing irAEs were: skin 19% (95% CI: 7–39%) and 95% (88–98%), muscles and joints 71% (48–89%) and 83% (75–90%), intestines 100% (75–100%) and 85% (77–91%); thyroid gland 92% (62–99%) and 95% (89–98%), lungs 75% (19–99%) and 90% (83–95%), and heart 50% (13–99%) and 97% (92–99%), respectively.
Conclusion
[
18
F]FDG-PET/CT generally had moderate to high sensitivities (except for skin and heart) and specificities in diagnosing irAEs in patients receiving adjuvant ICI; this could be suggested to be systematically assessed and reported in scan reports. |
| doi_str_mv | 10.1007/s11604-024-01554-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11217074</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3074228063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-e0516ff319343a9ceb5e1b9c4377d0535880e636060c5d8c20a4f41f74210e953</originalsourceid><addsrcrecordid>eNp9UUuLFDEQbkRx19U_4EECnuNWOunXSWTcWYWF9TCCIBIy6eruzE6n2yQ90j_K_2jm4agXD0UV-R5V4UuSlwzeMIDi2jOWg6CQxmJZJuj8KLlkZV5QBuWXx-e5YBfJM-83ALngQjxNLniZgQCAy-TnvWuVpX5EbRqjidJ6ckrPZGjIV1Yuvy3f39JPN6vrxYoYS0yNNphmNrYlpu8ni9ThVgWsiap36DwS3EWK35NHFcxh_mFCRzrTdtQZ_0D6qLBDr0hweJAecFVvpp2y4eRLdIf6YRzM_sV2Zm3C4J4nTxq19fji1K-Sz8ub1eIDvbu__bh4d0c1r3igCBnLm4aziguuKo3rDNm60oIXRQ0Zz8oSMOc55KCzutQpKNEI1hQiZYBVxq-St0ffcVr3WOv4C6e2cnSmV26WgzLyX8SaTrbDTjKWsgIKER1enxzc8H1CH-RmmJyNR0se8TQtIeeRlR5Z2g3eO2zOKxjIfcbymLGMGctDxnKOold_H3eW_A41EviR4CNkW3R_dv_H9hci47Xk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3074228063</pqid></control><display><type>article</type><title>Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor</title><source>Springer Online Journals</source><creator>Gideonse, Birte Molvik ; Birkeland, Magnus ; Vilstrup, Mie Holm ; Grupe, Peter ; Naghavi-Behzad, Mohammad ; Ruhlmann, Christina H. ; Gerke, Oke ; Hildebrandt, Malene Grubbe</creator><creatorcontrib>Gideonse, Birte Molvik ; Birkeland, Magnus ; Vilstrup, Mie Holm ; Grupe, Peter ; Naghavi-Behzad, Mohammad ; Ruhlmann, Christina H. ; Gerke, Oke ; Hildebrandt, Malene Grubbe</creatorcontrib><description>Purpose
This study aimed to determine the organ-specific accuracy of [
18
F]FDG-PET/CT in identifying immune-related adverse events (irAEs) in patients with high-risk (stage III/IV) surgically resected melanoma treated with an adjuvant immune checkpoint inhibitor (ICI) and determine the incidence of irAEs within the first year after starting treatment.
Materials and methods
This registry-based study included individuals who had undergone surgical removal of melanoma and were undergoing adjuvant ICI treatment (either nivolumab or pembrolizumab). The study specifically enrolled patients who had undergone both a baseline and at least one subsequent follow-up [
18
F]FDG-PET/CT scan. Follow-up scans were performed every third month in the first year after surgery to screen for disease recurrence. We retrospectively compared the follow-up scans with baseline scans to identify irAEs. Clinical information on irAEs was obtained from medical records and served as a reference standard for determining the accuracy of [
18
F]FDG-PET/CT.
Results
A total of 123 patients with 363 [
18
F]FDG-PET/CT scans were included, and 65 patients (52.8%) developed irAEs. In decreasing order, the organ-specific incidences of irAEs were: skin 26/65 (40%), muscle and joints 21/65 (32.3%), intestines 13/65 (20%), thyroid gland 12/65 (18.5%), lungs 4/65 (6.2%), and heart 2/65 (3.1%). The sensitivities and specificities of [
18
F]FDG-PET/CT for diagnosing irAEs were: skin 19% (95% CI: 7–39%) and 95% (88–98%), muscles and joints 71% (48–89%) and 83% (75–90%), intestines 100% (75–100%) and 85% (77–91%); thyroid gland 92% (62–99%) and 95% (89–98%), lungs 75% (19–99%) and 90% (83–95%), and heart 50% (13–99%) and 97% (92–99%), respectively.
Conclusion
[
18
F]FDG-PET/CT generally had moderate to high sensitivities (except for skin and heart) and specificities in diagnosing irAEs in patients receiving adjuvant ICI; this could be suggested to be systematically assessed and reported in scan reports.</description><identifier>ISSN: 1867-1071</identifier><identifier>EISSN: 1867-108X</identifier><identifier>DOI: 10.1007/s11604-024-01554-y</identifier><identifier>PMID: 38504000</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Accuracy ; Adverse events ; Computed tomography ; Fluorine isotopes ; Health services ; Heart ; Imaging ; Immune checkpoint inhibitors ; Inhibitors ; Intestine ; Lungs ; Medical records ; Medicine ; Medicine & Public Health ; Melanoma ; Muscles ; Nuclear Medicine ; Original ; Original Article ; Patients ; Pembrolizumab ; Positron emission ; Radiology ; Radiotherapy ; Skin ; Thyroid ; Thyroid gland</subject><ispartof>Japanese journal of radiology, 2024-07, Vol.42 (7), p.753-764</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c393t-e0516ff319343a9ceb5e1b9c4377d0535880e636060c5d8c20a4f41f74210e953</cites><orcidid>0000-0002-6761-8126</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11604-024-01554-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11604-024-01554-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38504000$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gideonse, Birte Molvik</creatorcontrib><creatorcontrib>Birkeland, Magnus</creatorcontrib><creatorcontrib>Vilstrup, Mie Holm</creatorcontrib><creatorcontrib>Grupe, Peter</creatorcontrib><creatorcontrib>Naghavi-Behzad, Mohammad</creatorcontrib><creatorcontrib>Ruhlmann, Christina H.</creatorcontrib><creatorcontrib>Gerke, Oke</creatorcontrib><creatorcontrib>Hildebrandt, Malene Grubbe</creatorcontrib><title>Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor</title><title>Japanese journal of radiology</title><addtitle>Jpn J Radiol</addtitle><addtitle>Jpn J Radiol</addtitle><description>Purpose
This study aimed to determine the organ-specific accuracy of [
18
F]FDG-PET/CT in identifying immune-related adverse events (irAEs) in patients with high-risk (stage III/IV) surgically resected melanoma treated with an adjuvant immune checkpoint inhibitor (ICI) and determine the incidence of irAEs within the first year after starting treatment.
Materials and methods
This registry-based study included individuals who had undergone surgical removal of melanoma and were undergoing adjuvant ICI treatment (either nivolumab or pembrolizumab). The study specifically enrolled patients who had undergone both a baseline and at least one subsequent follow-up [
18
F]FDG-PET/CT scan. Follow-up scans were performed every third month in the first year after surgery to screen for disease recurrence. We retrospectively compared the follow-up scans with baseline scans to identify irAEs. Clinical information on irAEs was obtained from medical records and served as a reference standard for determining the accuracy of [
18
F]FDG-PET/CT.
Results
A total of 123 patients with 363 [
18
F]FDG-PET/CT scans were included, and 65 patients (52.8%) developed irAEs. In decreasing order, the organ-specific incidences of irAEs were: skin 26/65 (40%), muscle and joints 21/65 (32.3%), intestines 13/65 (20%), thyroid gland 12/65 (18.5%), lungs 4/65 (6.2%), and heart 2/65 (3.1%). The sensitivities and specificities of [
18
F]FDG-PET/CT for diagnosing irAEs were: skin 19% (95% CI: 7–39%) and 95% (88–98%), muscles and joints 71% (48–89%) and 83% (75–90%), intestines 100% (75–100%) and 85% (77–91%); thyroid gland 92% (62–99%) and 95% (89–98%), lungs 75% (19–99%) and 90% (83–95%), and heart 50% (13–99%) and 97% (92–99%), respectively.
Conclusion
[
18
F]FDG-PET/CT generally had moderate to high sensitivities (except for skin and heart) and specificities in diagnosing irAEs in patients receiving adjuvant ICI; this could be suggested to be systematically assessed and reported in scan reports.</description><subject>Accuracy</subject><subject>Adverse events</subject><subject>Computed tomography</subject><subject>Fluorine isotopes</subject><subject>Health services</subject><subject>Heart</subject><subject>Imaging</subject><subject>Immune checkpoint inhibitors</subject><subject>Inhibitors</subject><subject>Intestine</subject><subject>Lungs</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanoma</subject><subject>Muscles</subject><subject>Nuclear Medicine</subject><subject>Original</subject><subject>Original Article</subject><subject>Patients</subject><subject>Pembrolizumab</subject><subject>Positron emission</subject><subject>Radiology</subject><subject>Radiotherapy</subject><subject>Skin</subject><subject>Thyroid</subject><subject>Thyroid gland</subject><issn>1867-1071</issn><issn>1867-108X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9UUuLFDEQbkRx19U_4EECnuNWOunXSWTcWYWF9TCCIBIy6eruzE6n2yQ90j_K_2jm4agXD0UV-R5V4UuSlwzeMIDi2jOWg6CQxmJZJuj8KLlkZV5QBuWXx-e5YBfJM-83ALngQjxNLniZgQCAy-TnvWuVpX5EbRqjidJ6ckrPZGjIV1Yuvy3f39JPN6vrxYoYS0yNNphmNrYlpu8ni9ThVgWsiap36DwS3EWK35NHFcxh_mFCRzrTdtQZ_0D6qLBDr0hweJAecFVvpp2y4eRLdIf6YRzM_sV2Zm3C4J4nTxq19fji1K-Sz8ub1eIDvbu__bh4d0c1r3igCBnLm4aziguuKo3rDNm60oIXRQ0Zz8oSMOc55KCzutQpKNEI1hQiZYBVxq-St0ffcVr3WOv4C6e2cnSmV26WgzLyX8SaTrbDTjKWsgIKER1enxzc8H1CH-RmmJyNR0se8TQtIeeRlR5Z2g3eO2zOKxjIfcbymLGMGctDxnKOold_H3eW_A41EviR4CNkW3R_dv_H9hci47Xk</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Gideonse, Birte Molvik</creator><creator>Birkeland, Magnus</creator><creator>Vilstrup, Mie Holm</creator><creator>Grupe, Peter</creator><creator>Naghavi-Behzad, Mohammad</creator><creator>Ruhlmann, Christina H.</creator><creator>Gerke, Oke</creator><creator>Hildebrandt, Malene Grubbe</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6761-8126</orcidid></search><sort><creationdate>20240701</creationdate><title>Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor</title><author>Gideonse, Birte Molvik ; Birkeland, Magnus ; Vilstrup, Mie Holm ; Grupe, Peter ; Naghavi-Behzad, Mohammad ; Ruhlmann, Christina H. ; Gerke, Oke ; Hildebrandt, Malene Grubbe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-e0516ff319343a9ceb5e1b9c4377d0535880e636060c5d8c20a4f41f74210e953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Accuracy</topic><topic>Adverse events</topic><topic>Computed tomography</topic><topic>Fluorine isotopes</topic><topic>Health services</topic><topic>Heart</topic><topic>Imaging</topic><topic>Immune checkpoint inhibitors</topic><topic>Inhibitors</topic><topic>Intestine</topic><topic>Lungs</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanoma</topic><topic>Muscles</topic><topic>Nuclear Medicine</topic><topic>Original</topic><topic>Original Article</topic><topic>Patients</topic><topic>Pembrolizumab</topic><topic>Positron emission</topic><topic>Radiology</topic><topic>Radiotherapy</topic><topic>Skin</topic><topic>Thyroid</topic><topic>Thyroid gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gideonse, Birte Molvik</creatorcontrib><creatorcontrib>Birkeland, Magnus</creatorcontrib><creatorcontrib>Vilstrup, Mie Holm</creatorcontrib><creatorcontrib>Grupe, Peter</creatorcontrib><creatorcontrib>Naghavi-Behzad, Mohammad</creatorcontrib><creatorcontrib>Ruhlmann, Christina H.</creatorcontrib><creatorcontrib>Gerke, Oke</creatorcontrib><creatorcontrib>Hildebrandt, Malene Grubbe</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Japanese journal of radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gideonse, Birte Molvik</au><au>Birkeland, Magnus</au><au>Vilstrup, Mie Holm</au><au>Grupe, Peter</au><au>Naghavi-Behzad, Mohammad</au><au>Ruhlmann, Christina H.</au><au>Gerke, Oke</au><au>Hildebrandt, Malene Grubbe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor</atitle><jtitle>Japanese journal of radiology</jtitle><stitle>Jpn J Radiol</stitle><addtitle>Jpn J Radiol</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>42</volume><issue>7</issue><spage>753</spage><epage>764</epage><pages>753-764</pages><issn>1867-1071</issn><eissn>1867-108X</eissn><abstract>Purpose
This study aimed to determine the organ-specific accuracy of [
18
F]FDG-PET/CT in identifying immune-related adverse events (irAEs) in patients with high-risk (stage III/IV) surgically resected melanoma treated with an adjuvant immune checkpoint inhibitor (ICI) and determine the incidence of irAEs within the first year after starting treatment.
Materials and methods
This registry-based study included individuals who had undergone surgical removal of melanoma and were undergoing adjuvant ICI treatment (either nivolumab or pembrolizumab). The study specifically enrolled patients who had undergone both a baseline and at least one subsequent follow-up [
18
F]FDG-PET/CT scan. Follow-up scans were performed every third month in the first year after surgery to screen for disease recurrence. We retrospectively compared the follow-up scans with baseline scans to identify irAEs. Clinical information on irAEs was obtained from medical records and served as a reference standard for determining the accuracy of [
18
F]FDG-PET/CT.
Results
A total of 123 patients with 363 [
18
F]FDG-PET/CT scans were included, and 65 patients (52.8%) developed irAEs. In decreasing order, the organ-specific incidences of irAEs were: skin 26/65 (40%), muscle and joints 21/65 (32.3%), intestines 13/65 (20%), thyroid gland 12/65 (18.5%), lungs 4/65 (6.2%), and heart 2/65 (3.1%). The sensitivities and specificities of [
18
F]FDG-PET/CT for diagnosing irAEs were: skin 19% (95% CI: 7–39%) and 95% (88–98%), muscles and joints 71% (48–89%) and 83% (75–90%), intestines 100% (75–100%) and 85% (77–91%); thyroid gland 92% (62–99%) and 95% (89–98%), lungs 75% (19–99%) and 90% (83–95%), and heart 50% (13–99%) and 97% (92–99%), respectively.
Conclusion
[
18
F]FDG-PET/CT generally had moderate to high sensitivities (except for skin and heart) and specificities in diagnosing irAEs in patients receiving adjuvant ICI; this could be suggested to be systematically assessed and reported in scan reports.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>38504000</pmid><doi>10.1007/s11604-024-01554-y</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6761-8126</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1867-1071 |
| ispartof | Japanese journal of radiology, 2024-07, Vol.42 (7), p.753-764 |
| issn | 1867-1071 1867-108X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11217074 |
| source | Springer Online Journals |
| subjects | Accuracy Adverse events Computed tomography Fluorine isotopes Health services Heart Imaging Immune checkpoint inhibitors Inhibitors Intestine Lungs Medical records Medicine Medicine & Public Health Melanoma Muscles Nuclear Medicine Original Original Article Patients Pembrolizumab Positron emission Radiology Radiotherapy Skin Thyroid Thyroid gland |
| title | Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T14%3A59%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Organ-specific%20accuracy%20of%20%5B18F%5DFDG-PET/CT%20in%20identifying%20immune-related%20adverse%20events%20in%20patients%20with%20high-risk%20melanoma%20treated%20with%20adjuvant%20immune%20checkpoint%20inhibitor&rft.jtitle=Japanese%20journal%20of%20radiology&rft.au=Gideonse,%20Birte%20Molvik&rft.date=2024-07-01&rft.volume=42&rft.issue=7&rft.spage=753&rft.epage=764&rft.pages=753-764&rft.issn=1867-1071&rft.eissn=1867-108X&rft_id=info:doi/10.1007/s11604-024-01554-y&rft_dat=%3Cproquest_pubme%3E3074228063%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3074228063&rft_id=info:pmid/38504000&rfr_iscdi=true |